A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: A four year survival update.

Authors:

Abstract
No abstract available
Funding Information
  • Clovis Oncology
  • Basser Center for BRCA.